Navigation Links
Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
Date:11/22/2011

SHELTON, Conn., Nov. 22, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the initiation of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, kappa opioid agonist, CR845, in healthy volunteers. The double-blind, placebo-controlled trial is expected to enroll up to 60 subjects at a single U.S. site and will evaluate the pharmacokinetic, pharmacodynamic and safety profile of single escalating doses of CR845 in enteric-coated capsules. An intravenous formulation of CR845 is currently in Phase II development for the treatment of acute postoperative pain with data expected in 1Q'12. 

"Initiation of this Phase I trial represents an important advancement in the clinical potential of CR845 and will provide the basis for developing the drug beyond the treatment of acute pain in a hospital setting," said Frederique Menzaghi, V.P. of R&D at Cara Therapeutics. "There remains a significant unmet need among chronic pain patients for an effective analgesic without the debilitating or dangerous side-effects of currently used narcotic analgesics and NSAIDs. We believe that an oral formulation of CR845 has the potential to provide an effective and safer option for the treatment of chronic pain."

About CR845

CR845 is a highly selective, peptide-based, peripherally-restricted kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain.  In a previous randomized, placebo-controlled Phase II study, CR845 demonstrated evidence of analgesic efficacy when administered as a single intravenous dose to women following laparoscopic hysterectomy.  In addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids (narcotics) and showed a significant reduction in the incidence of post-operative nausea and vomiting. A multicenter double-blind, randomized, placebo-controlled 200-patient Phas
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
2. Prime Therapeutics Launches Retail Medication Therapy Management Program
3. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
4. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
5. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
7. Echo Therapeutics Announces Third Quarter 2011 Financial Results
8. PTC Therapeutics Receives Grand Challenges Explorations Funding
9. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... Amerivet Solutions, LLC ( AMERIVET ), ... government from Federal to Municipal, is pleased to ... include complex metal design and fabrication manufacturing. "We ... aluminum parts for the Defense Logistics Agency (DLA) ... service government contracts," states Richard Bergen , ...
Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2Drug Patent Watch 2Drug Patent Watch 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... Jan. 31, 2012  Kerry Ingredients & Flavours is expanding ... include a new Cell Science laboratory. Building on the ... the new Cell Science laboratory will incorporate state-of-the-art technologies ... bio-pharma customers and technology partners. "The ...
... Jan. 31, 2012  Par Pharmaceutical Companies, Inc. (NYSE: PRX ... live webcast on Tuesday, February 28, 2012 at 9:00 AM EST ... The Company will release its financial results on February 28, 2012 ... can be made via the Company,s website at www.parpharm.com . ...
Cached Medicine Technology:Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers Globally 2
(Date:6/19/2013)... 19, 2013 Ultimate Medical Academy (UMA) ... 11.5-hour broadcast on WFLA News Channel 8. Since its ... than $84 million for All Children's Hospital in St. ... "30 Years of Miracles," marked the second year UMA ... employees worked the phones during the Telethon, which raised ...
(Date:6/19/2013)... 2013 The former internist for the ... MD, now serves as director of prevention and wellness ... his own personal encounter with a metabolic syndrome diagnosis ... Over Knives , that he credits with sparking the ... his medical practice. , “The average medical student gets ...
(Date:6/19/2013)... 19, 2013 Next Thursday, June ... kids entertainment media organization, and Muzzy Lane ... will be introducing the Games for Health community ... game is geared toward students in grades 4-7 ... lifestyles by rewarding positive choices. The game is ...
(Date:6/19/2013)... Imprivata ®, a leading global provider of ... OneSign ® leads the single sign-on (SSO) category in ... Services report . CIOs and other healthcare executives iwere ... of its products and the quality of its customer ... integral to their long-term healthcare IT strategy. , ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was ... their third in a series of six workshops where people with ... helped place the mosaic tiles in their permanent location under the ... and Greg Maxwell. , This mural project began in March ... root over three years ago with the goal of promoting ...
Breaking Medicine News(10 mins):Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2
... efforts to cut back, , , SATURDAY, April 25 (HealthDay News) ... important lifestyle changes people with heart failure can make, but ... has found. , Researchers asked 116 people with heart ... Though the recommended daily intake of sodium for people with ...
... more potent treatment with fewer side effects , , SATURDAY, ... more direct delivery of cancer drugs to tumors have ... safe, biodegradable polymer, the nanoparticles are chemically engineered to ... most human tumors, and to carry a higher concentration ...
... - Plastic Surgery increased too, with breast implants and ... bank balances and stunning senior celebs are influencing factors.MANCHESTER, ... has been seen by staff at Transform, the UK,s ... Botox Grannies.More and more women over 60 are having ...
... Research , an association of technology analysts, market researchers, and science ... for expanding the pool of associates and tripling of publication schedule ... ... 2009 -- STIX Market Research , an association of technology ...
... a person,s insurance coverage affect their access to quality ... Center, insurance coverage may not only affect a patient,s ... care they receive. Research findings, presented today at the ... a national debate on healthcare reform. , "We ...
... Ill., April 24 World Veterinary Day, April 25, ... farmers. "This year,s theme, ,Veterinarians and Livestock ... partnership, highlights a discipline of veterinary medicine ... said Dr. W. Ron DeHaven, DVM, MBA, Chief Executive ...
Cached Medicine News:Health News:Hidden Salt in Diet Haunts Many With Heart Failure 2Health News:Nanoparticles May Help Attack Cancer More Directly 2Health News:Growth of Plastic Surgery & Botox Grannies in UK 2Health News:Growth of Plastic Surgery & Botox Grannies in UK 3Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 2Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 3Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 4Health News:Does a person's insurance coverage affect their access to quality cancer care? 2Health News:AVMA Celebrates World Veterinary Day 2
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Optik K & Rs bandage lens is a high water content, therapeutic lens which is ideal for practitioners who recognize the importance of a quality bandage lens....
John weiss, wright acrylic globe....
Medicine Products: